What is Stephens's price target for GKOS?

Stephens's latest stated price target for Glaukos Corporation (GKOS) is $69, from its action on Oct 14, 2022.

What is Stephens's rating on GKOS?

Stephens rates GKOS Overweight, a bullish rating, as of Oct 14, 2022.

When did Stephens last change its view on GKOS?

On Oct 14, 2022, Stephens resumes coverage at Overweight, price target $69.

Stephens GKOS price target and rating history

Glaukos Corporation (GKOS) · Health Care

Stephens rates Glaukos Corporation (GKOS) Overweight with a $69 price target, as of its latest action on Oct 14, 2022. It has published 4 rating actions on GKOS since July 2021, including 1 upgrade and 1 downgrade.

Current rating: Overweight
Price target: $69
Median target, all firms: Too few
Actions on GKOS: 4

Stephens price target on GKOS

Stephens price target on GKOS, each point a stated target, July 2021 to October 2022.

Every Stephens rating on GKOS

Oct 14, 2022
ResumeStephens resumes coverage at Overweight, price target $69
Nov 3, 2021
UpgradeStephens upgrades to Overweight from Equal-Weight, price target $60 to $68
Aug 6, 2021
ReiterateStephens cuts its price target to $60 from $70, keeps Equal-Weight
Jul 26, 2021
DowngradeStephens downgrades to Equal-Weight from Overweight, price target $70

How other firms rate GKOS

Each firm's latest rating and stated target in the last 12 months.

Firm	Rating	Price target	Date
UBS	Neutral		Jul 28, 2026
H.C. Wainwright	Buy	$168	Jul 6, 2026

Questions about Stephens and GKOS

What is Stephens's price target for GKOS?: Stephens's latest stated price target for Glaukos Corporation (GKOS) is $69, from its action on Oct 14, 2022.
What is Stephens's rating on GKOS?: Stephens rates GKOS Overweight, a bullish rating, as of Oct 14, 2022.
When did Stephens last change its view on GKOS?: On Oct 14, 2022, Stephens resumes coverage at Overweight, price target $69.

More GKOS rating histories

All Stephens ratings GKOS news and filings Every analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.